Skip to content

R&D at other companies

UFP Technologies logo
UFP TechnologiesUFPT
$2.15M-17.3%
Merit Medical Systems logo
Merit Medical SystemsMMSI
$22.61M+0.6%
Solventum logo
SolventumSOLV
$189M-2.1%
iRadimed logo
iRadimedIRMD
$956K+53.2%
ICU Medical logo
ICU MedicalICUI
$21.28M-8.6%
Tactile Systems Technology logo
Tactile Systems TechnologyTCMD
$2.78M+59.4%

Other financials

Income statement

See full
Revenue$75.4M+27.5%
Gross profit$42.8M+28.7%
Operating income$4.3M+11.8%
Net income$2.6M-1.6%
EPS (diluted)$0.060.0%

Balance sheet

See full
Cash & equivalents$9.8M-3.9%
Total debt$12.4M+84.0%
Total equity$143.9M+6.8%
Total assets$197.4M+10.8%

Cash flow

See full
Operating cash flow$8.1M+183%
CapEx$6.7M-56.6%
Free cash flow$1.4M+111%

Valuation

See full
Market cap$448.16M+71.3%
Enterprise value$450.83M+74.6%
P/E30.1×+8.8×
P/S1.6×+0.4×

Profitability

See full
Gross margin57.6%-1.1pp
Operating margin8.2%-0.2pp
Net margin5.2%-0.1pp
FCF margin9%

Returns & leverage

See full
Return on equity10.7%+0.9pp
Debt / equity0.1×0.0×
Current ratio1.2×-0.2×

Where this comes from

Reported directly by Viemed Healthcare, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Viemed Healthcare, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Viemed Healthcare, Inc.'s r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Viemed Healthcare, Inc.'s R&D?
Viemed Healthcare, Inc. (VMD) reported R&D of $579K in Q1 2026.
How has Viemed Healthcare, Inc.'s R&D changed year-over-year?
Viemed Healthcare, Inc.'s R&D decreased by 27.4% year-over-year, from $797K to $579K.
What is the long-term trend for Viemed Healthcare, Inc.'s R&D?
Over 4 years (2021 to 2025), Viemed Healthcare, Inc.'s R&D has grown at a 9.4% compound annual growth rate (CAGR), from $2.11M to $3.02M.
What does R&D mean?
Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.